# Reflect Scientific, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [Reflect Scientific, Inc.](/companies/rscf.md) (CIK 1103090)
- Form: 10-Q
- Filed: 2019-11-19
- Accepted by EDGAR: Nov 18, 2019, 18:08 ET
- Period: 2019-09-30
- Accession: 0001548123-19-000223
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1103090/000154812319000223/f10-qq3-2019v7clean.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1103090/000154812319000223/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $366.4k | us-gaap:Revenues |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $977.3k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $101.4k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $300.9k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $265.1k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $676.4k | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $75.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $105.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $3.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$21.7k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $1.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$22.2k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $237.5k | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2019-09-30 | $457.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $684.0k | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $813.0k | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $304.7k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $317.5k | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $495.5k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 10,620 characters.

#### Special Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Annual Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance however, that management’s expectations will necessarily come to pass. Factors that may affect forward- looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest;

Changes in U.S., global or regional economic conditions;

Changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments;

Increased competitive pressures, both domestically and internationally;

Legal and regulatory developments, such as regulatory actions affecting environmental activities;

The imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls;

Adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

#### Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Financial Statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. The Company has adopted the new revenue recognition and lease accounting standards. The Company believes there have been no other significant changes during the nine-month period ended September 30, 2019, to the items disclosed as significant accounting policies in management's Notes to the Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2018.

#### Plan of Operation and Business Growth

Our efforts continue to be focused on increasing the sales of our life science consumables while, at the same time, working to enhance the design of our liquid nitrogen refrigeration products. Of those liquid nitrogen refrigeration products, the ultra-low temperature freezer is receiving highest priority. We have received positive feedback of the improvements and enhancements made to the design of the ultra-low temperature freezer. We also continue work on the refrigerated trailer, or “reefer.”

We are receiving considerable interest in our latest product introduction, which is an ultra-cold chiller used in the manufacture of CBD oil. This unit improves the efficiency of the manufacturing process and enables the production of a higher purity in the CBD oil produced.

Concurrent with the development and commercialization of the above products, we have completed our on-line catalog and are making progress in enrolling new distributors for our consumable products.

An analysis of operating results for the three months ended September 30, 2019 and 2018 follows.

#### Results of Operations

#### Three Months Ended September 30, 2019 and 2018

|  | For the three months ended September 30, 2019 | 2018 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $366,431 | $359,151 | $7,280 |
| Cost of goods sold | 101,366 | 151,178 | (49,812) |
| Gross profit | 265,065 | 207,973 | 57,092 |
| Operating expenses | 261,828 | 250,090 | 11,738 |
| Other expense | 1,716 | 456 | 1,260 |
| Net profit (loss) | $1,521 | $(42,573) | $44,094 |

Revenues increased during the three-month period ended September 30, 2019, to $366,431 from $359,151 for the three-month period ended September 30, 2018, an increase of $7,280 The increase results primarily from increased sale of ultra-low temperature freezers. We are continuing work to increase our market penetration in the ultra-low temperature freezer market and in the ultra-cold chiller.

Cost of goods decreased in the quarter ending September 30, 2019, as compared to September 30, 2018, to $101,366 from $151,178, a decrease of $49,812. We realized a gross profit percentage of 72% for the three months ended September 30, 2019, compared to 58% for the three months ended September 30, 2018. The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter. The increases sale of freezers during this period provided the higher margins. We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on all product lines.

Operating expenses increased to $261,828 in the three months ended September 30, 2019, an increase of

$11,738 over the expenses of $250,090 incurred in the three-month period ended September 30, 2018. The increase results from small increases in a number of expense accounts. While we continue to monitor and minimize operating costs, we also realize that certain levels of expenditures are required in order to commercialize the products and achieve market penetration.

Research and development expenses for the three months ended September 30, 2019 were $75,417, an increase of $40,875 in expenses for the same period in 2018, due to development work on the ultra-cold CBD oil chiller. R&D expenses are expected to remain above the prior year level as work continues to commercialize this unit.

Net income for the three-month period ended September 30, 2019 was $1,521, which compares to a net loss of $42,573 for the three-month period ended September 30, 2018. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

The net income of $1,521 for the three-month period ended September 30, 2019 represents income of $0.00 per share. This compares to the net loss of $42,573, or loss of $0.00 per share, for the three months ended September 30, 2018.

#### Nine Months Ended September 30, 2019 and 2018

|  | For the nine months ended September 30, 2019 | 2018 | Change |
| --- | ---: | ---: | ---: |
| Revenues | $977,312 | $1,119,491 | $(142,179) |
| Cost of goods sold | 300,901 | 381,015 | (80,114) |
| Gross profit | 676,411 | 738,476 | (62,065) |
| Operating expenses | 698,072 | 899,619 | (201,547) |
| Other income (expense) | 583 | 456 | 127 |
| Net loss | $(22,244) | $(161,599) | $(139,355) |

Revenues decreased during the nine months ended September 30, 2019, to $977,312 from $1,119,491 for the nine months ended September 30, 2018, a decrease of $142,179. The decrease results primarily lower sales of specialty lab supplies. We are continuing work to increase our sales of specialty lab products.

Cost of goods decreased in the quarter ending September 30, 2019, as compared to September 30, 2018, to $300,901 from $381,015 a decrease of $80,114. We realized a gross profit percentage of 69% for the nine months ended September 30, 2019, compared to 69% for the nine months ended September 30, 2018. The gross profit percentage is dependent on the mix of product sales, which varies from quarter to quarter. We continue to actively work to obtain more favorable pricing from our vendors in order to increase the margins realized on all product lines.

Operating expenses decreased to $698,072 in the nine months ended September 30, 2019, a decrease of $201,547 over the expenses of $899,619 incurred in the nine-month period ended September 30, 2018. The decrease results primarily from stock-based consulting fees and stock-based compensation paid in 2018. While we continue to monitor and minimize operating costs, we also realize that certain levels of expenditures are required in order to commercialize the products and achieve market penetration.

Research and development expenses for the nine months ended September 30, 2019 were $105,040, an increase of $55,593 in expenses for the same period in 2018, due to development work on the ultra-cold CBD oil chiller. R&D expenses are expected to remain above the prior year level as work continues to commercialize this unit.

The net loss for the nine-month period ended September 30, 2019 was $22,244, which compares to a net loss of $161,599 for the nine-month period ended September 30, 2018. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

The net loss of $22,244 for the nine-month period ended September 30, 2019 represents a loss of $0.00 per share. This compares to the net loss of $161,599, or $0.00 per share, for the nine months ended September 30, 2018.

#### Seasonality and Cyclicality

We do not believe our business is cyclical.

#### Liquidity and Capital Resources

Our cash resources at September 30, 2019, were $457,094, with accounts receivable of $40,689, net of allowance, and inventory of $182,724, net of allowance. Our working capital on September 30, 2019, was $379,358. Working capital on December 31, 2018 was $446,877.

For the nine-month period ended September 30, 2019, net cash provided by operating activities was $237,535 which compares to $67,371 net cash used in operating activities for the nine-month period ended September 30, 2018.

### Off-Balance Sheet Arrangements

None.

## Controls and procedures

As filed, 2,101 characters.

### (a)

### Evaluation of Disclosure Controls and Procedures.

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods, and is accumulated and communicated to management, including our Chief Executive Officer and

Principal Financial Officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures are not effective at that reasonable assurance level as of the end of the period covered by this report based upon our current level of transactions and staff. However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote

### (b)

### Changes in Internal Control Over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act. Management reviewed our internal controls over financial reporting, and there have been no changes in our internal controls over financial reporting for the nine-month period ended September 30, 2019 that have materially affected, or are like to affect, our internal controls over financial reporting.

Filed Nov 19, 2019.
Source: SEC EDGAR, the filing index for accession 0001548123-19-000223. Last ingested by Listed: Oct 24, 2026, 15:01 ET. No prices; not investment advice.